•    For patients undergoing chemotherapy and/or radiation treatment, it could spell the end of painful lesions of the mouth, tongue and throat that leave many people unable to eat, speak and continue their life-saving treatments.

Oral mucositis related infections frequently require hospitalization and in some cases lead to death.

•    For oncologists it could provide the ability to administer newer, more effective chemotherapeutic agents without concern for the harsh side effects that cause some patients to halt treatments.  Eliminating oral mucositis symptoms would allow doctors to focus their full attention on the underlying cancer.

•    Health insurance companies would see the cost of care reduced significantly, as cancer patients avoid the need for oral mucositis-related medical intervention and hospitalizations.

•    For the successful biotech companies, the global market for oral mucositis treatment and/or prevention could reach $5 billion annually.  That represents a huge worldwide market to be served by one or more successful biotech companies, all of whom are currently comparatively small in size.